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Abstract: The concept that disease rooted principally in
chronic aberrant constitutive and reactive activation of
mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last
decade has recognition of “mast cell activation syndrome”
(MCAS) grown significantly. Two principal proposals for
diagnostic criteria have emerged. One, originally published in 2012, is labeled by its authors as a “consensus”
(re-termed here as “consensus-1”). Another sizable contingent of investigators and practitioners favor a different approach (originally published in 2011, newly termed
here as “consensus-2”), resembling “consensus-1” in
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some respects but differing in others, leading to substantial differences between these proposals in the numbers
of patients qualifying for diagnosis (and thus treatment).
Overdiagnosis by “consensus-2” criteria has potential to
be problematic, but underdiagnosis by “consensus-1”
criteria seems the far larger problem given (1) increasing appreciation that MCAS is prevalent (up to 17% of the
general population), and (2) most MCAS patients, regardless of illness duration prior to diagnosis, can eventually
identify treatment yielding sustained improvement. We
analyze these proposals (and others) and suggest that,
until careful research provides more definitive answers,
diagnosis by either proposal is valid, reasonable, and
helpful.
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The concept that a class of diseases rooted principally just
in chronic aberrant constitutive and/or reactive activation of mast cells (MCs; and with only modest increases
in MC numbers due to reduced apoptosis rather than the
marked MC neoplasia defining the rare disorder of mastocytosis) ought to exist was first published in 1984–1991
[1–3]. The heterogeneity of the full range of such patients’
clinical presentations is extreme, but symptoms/findings (typically waxing/waning and migratory) often
include flushing, allergic-type issues, fatigue, dermatographism, cognitive dysfunction, irritated eyes/nose/
mouth/throat, adenitis, dyspnea, palpitations, nausea,
reflux, abdominal pain, diarrhea (often alternating with
constipation), interstitial cystitis, vulvovaginitis, menorrhagia, dysmenorrhea, fibromyalgia-type pain, joint
hypermobility, benign growth anomalies (e.g. cysts, fibrosis, vascular anomalies, poor healing), headache, sensory

neuropathy, dysautonomias (e.g. orthostatic hypotension,
blood pressure and heart rate lability, thermal dysregulation), anxiety and mood disorders, and an assortment of
metabolic/endocrinologic (e.g. thyroid) aberrancies. In
2007, the first case reports were published [4, 5], followed
shortly by a limited proposal for diagnostic criteria in cases
where MC clonality could be identified [6]. Subsequent
literature regarding this newly recognized (but of course
not truly new) “mast cell activation syndrome” (MCAS)
included case reports as well as formal studies (mostly
relatively small scale), reviews, and various proposals for
formal diagnostic criteria. Two principal such proposals
emerged – the first published initially in late 2010 [7] and
the second published initially in early 2011 [8]. The former
proposal was adjusted by its authors and others and republished in 2012 [9], labeled by them at that time as a
“consensus.” However, followers of MCAS literature know
there is another sizable world-wide contingent of investigators and practitioners – and patients – who feel there
are significant problems with the “consensus” approach
and who thus favor the alternative approach advocated by
the authors of the 2011 paper, which resembles the “consensus” approach in some respects but differs in a number
of other respects. An important difference between these
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proposals is the number of patients who would qualify for
an MCAS diagnosis. Underdiagnosis by inappropriately
restrictive criteria is dangerous given (1) increasing evidence of substantial prevalence of MCAS (various publications, based on varying amounts of data, have provided
estimates ranging from “rare” [10] to as high as 17% of the
general population [11], the latter perhaps unsurprising
given the increasingly recognized great prevalence of a
wide range of allergic and inflammatory disorders which
may be rooted at least partly in MCAS), and (2) experience
to date (e.g. [12]) suggesting that most MCAS patients,
regardless of the (typically decades long) duration of
their complex multisystem unwellness prior to diagnosis,
eventually identify some regimen which helps them gain
significant, largely sustainable improvement. Overdiagnosis, however, also could be problematic. Furthermore,
the very recent recognition of “hereditary alpha-tryptasemia” [HAT, a prevalent condition featuring (1) redundancy of the TPSAB1 gene expressing alpha-tryptase and
(2) many of the same clinical features as MCAS] is another
confounder in the challenges facing the diagnostician
considering MCAS. Given that the original proposals for
both of the principal schools of MCAS diagnostic thought
were first published nearly a decade ago and that multiple updates of each have been published since, we feel
that review, and a frank discussion of the pros and cons,
of the two proposals, as well as how HAT now “fits in” to
diagnostic considerations of MCAS, would be helpful. We
follow this analysis with our recommendations for steps
forward in research and in practice.
Before diving into this analysis, though, a brief overview of what MCAS is – or at least what it is thought by
most to be – may be helpful. The different “schools of
thought” proposing different diagnostic criteria have different senses of what the entity of MCAS encompasses,
and these different senses drive the differences in diagnostic criteria. However, there is much about MCAS which
is uncontested. It is helpful to understand these areas first.
Prior to the introduction of the term “mast cell activation disease” (MCAD) [7], “mast cell disease” was the
moniker usually used to refer to the full spectrum of diseases of the MC, which consisted principally of assorted
forms of the rare disease of mastocytosis and assorted
allergic diseases of varying prevalence ranging from rare
(e.g. certain urticarias) to common (e.g. environmental and
food allergies). That the allergic illnesses very commonly
reflect aberrant MC activation (MCA) was a background
biological fact largely lost from conscious consideration in
everyday practice. Also often lost was the consideration as
to what manifestations of MCA other than “allergic-type”
phenomena might also be present in allergy patients.
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These patients often experience “non-allergic” problems
(commonly inflammatory, sometimes even dystrophic)
(see Table 1) potentially rooted in chronic aberrant MCA
but which are left to be addressed by non-allergists even
less likely to recognize those problems as rooted in MCA.
Thus, the only “MC disease” recognized by most health
professionals until recently was the range of (prevalent)
overtly allergic-type phenomena and (rare) mastocytosis.
In the last 10–15 years, though, it has become apparent that most of the clinical problems in patients with any
form of “MC disease” – even mastocytosis – are rooted in
the aberrant activation of the abnormal MCs (i.e. aberrant
MC mediator production/release), thus leading to the designation of the new term of MCAD to describe the full spectrum of MC diseases, constantly reminding all clinicians of
the critical issue of aberrant MC activation in these patients.
Because it also became apparent that some MCAD patients
did not have either mastocytosis or merely the various
defined allergic-type phenomena but in fact a wide range
of clinical consequences of MCA, the term “mast cell activation syndrome” was coined to refer broadly to this entity [7].
Table 1 lists symptoms/problems which various MCAS
patients commonly exhibit consequent (directly or indirectly) to chronic aberrant MC mediator expression. Other
elements, too, though, are needed to make a clear diagnosis of MCAS, and disputes have arisen regarding these
elements. For one, laboratory evidence of MCA is highly
desirable. However, even if one sets aside arguments about
which laboratory criteria should be deemed supportive of
an MCAS diagnosis, mere acquisition of laboratory evidence is problematic for much of the world’s population
without access to these tests. As such, consideration needs
to be given to methods of diagnosing MCAS in situations
where testing is unobtainable, but disputes have led to differences in diagnostic criteria proposals, thus challenging
diagnosticians. Other areas of dispute were therapeutic in
nature, namely, the validity of, and approach to, (1) treating patients who have not yet acquired laboratory evidence
and (2) incorporating treatment results into diagnostic criteria. Given that impact potentially extends to millions of
patients (if the higher estimates of prevalence are closer to
the truth), we feel these differences warrant detailed analysis and open discussion.
We focus this paper on (1) rare patients with primary
(i.e. clonal) MCAS proven by the presently very limited
range of laboratory testing routinely available for proving
such [KIT-D816X mutational analysis, and flow cytometry seeking co-expression on the surfaces of MCs of
CD117 (the extracellular domain of transmembrane tyrosine kinase KIT, the dominant MC regulatory element)
together with CD25 (the alpha chain of the interleukin-2
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Table 1: Common symptoms and findings in MCAD.
System

Potential manifestations of MCAD

Constitutional

Fatigue, subjective or objective hyperthermia and/or hypothermia, sweats, flushing, plethora or pallor,
increased or decreased appetite, weight gain or loss, migratory pruritus, chemical/physical sensitivities (often
“odd”), poor healing
Dermatographism, rashes/lesions of many sorts (migratory patchy macular erythema, telangiectasias,
angiomata, xerosis, striae, warts, tags, folliculitis, ulcers, dyshydrotic eczema), angioedema, alopecia,
onychodystrophy (e.g. brittle and/or longitudinally ridged nails)
Irritated (often “dry”) eyes, episodic difficulty focusing, lid tremor/tic (blepharospasm)
Infectious or sterile otitis externa and/or media, hearing loss and/or tinnitus, dysosmia, coryza, post-nasal drip,
congestion, epistaxis
Pain or irritation (sometimes “burning”), leukoplakia, ulcers, angioedema, dysgeusia, dental and/or periodontal
inflammation/decay despite good personal and professional attention to dental hygiene
Adenopathy (usually sub-pathologic and spontaneously waxing/waning in size, often migratory), adenitis,
splenitis (typically only modest)
Airway inflammation at any or all levels, cough, dyspnea (usually mild, episodic, “just can’t catch a deep breath”
despite normal pulmonary function tests), wheezing (usually quite mild), obstructive sleep apnea regardless of
weight
Presyncope [co-diagnosis of postural orthostatic tachycardia syndrome (POTS) is common; full syncope
is relatively rare], hypertension, blood pressure lability, palpitations (usually not correlating with
electrocardiographic events), migratory edema, chest pain (usually non-anginal), atherosclerosis, odd heart
failure (e.g. takotsubo), allergic angina (Kounis syndrome), vascular anomalies
Dyspepsia, gastroesophageal reflux, nausea, vomiting (sometimes cyclical), diarrhea and/or constipation (often
alternating), gastroparesis, angioedema, dysphagia (usually proximal), bloating/gas (usually post-prandial,
often acute/subacute, sometimes to the appearance of full pregnancy), migratory abdominal pain from luminal
or solid organ inflammation or distention, malabsorption; cholecystectomy is common, though often yielding
normal pathology; ascites is rare
Migratory luminal and solid organ inflammation (“urinary tract infection,” often culture-negative, is commonly
misdiagnosed instead of interstitial cystitis), chronic kidney disease, endometriosis, chronic back/flank/
abdominal pain, infertility, decreased libido, vulvodynia, vaginitis (often misdiagnosed as infectious), painful
and/or irregular dysmenorrhea, menorrhagia; miscarriages are common and occasionally signal an antiphospholipid antibody syndrome possibly rooted in MCAS
Migratory bone/joint/muscle pain (co-diagnosis of fibromyalgia is common), joint laxity/hypermobility
[co-diagnosis of hypermobile Ehlers-Danlos syndrome (hEDS) is common], osteopenia/osteoporosis
(osteosclerosis is seen but is rare), and other tissue growth/development anomalies (i.e. dystrophisms, usually
benign) such as cysts, fibrosis, vascular anomalies such as hemorrhoids, aneurysms, and arteriovenous
malformations, occasionally even liquid or solid malignancies
Headache, sensory neuropathies (most commonly episode/migratory paresthesias in the distal extremities),
episodic weakness (though proven motor neuropathy is rare), dysautonomias, seizure disorders,
“pseudoseizures” (likely dysautonomic events), cognitive dysfunction (most commonly memory, concentration,
and/or word-finding difficulties), dyssomnias (insomnia, frequent waking, hypersomnolence, non-restorative
sleep, restless legs; less commonly or rarely: sleep apnea, sleepwalking, sleep talking, sleep paralysis, night
terrors)
Mood disturbances (e.g. depression, anger/irritability, mood lability), anxiety disorders (anxiety, panic,
obsession-compulsion), attention deficit/hyperactivity; frank psychosis is rare
Abnormal electrolytes and liver function tests, hypo- or hyperthyroidism (often just sheer (but modest) lability
of thyroid function), dyslipidemia, impaired glucose control (hyperglycemia, hypoglycemia, glycemic lability),
hypo- or hyper-ferritinemia; nutritional deficiencies are often suspected but are relatively rare, more commonly
micronutrient than general protein/calorie), delayed puberty; adrenal dysfunction is often suspected but rarely
proven
Polycythemia or anemia [typically just mild, most commonly normocytic but sometimes macrocytic or microcytic;
other causes (e.g. iron deficiency), whether consequent to MCAS or not, must be ruled out and addressed;
note that “normal” erythropoietic parameters (a relative polycythemia?) may seem odd given the extent of
chronic multisystem inflammation], leukocytosis or leukopenia (typically mild), monocytosis or eosinophilia
or basophilia (typically modest, occasionally moderate or even robust), thrombocytosis or thrombocytopenia
(typically mild), arterial and/or venous thromboembolic disease, otherwise inexplicable “easy” bruising/
bleeding (co-diagnosis of mild type 1 von Willebrand disease is common, too); there usually is no histologic or
molecular evidence of MC aberrancy in the marrow in MCAS, but sometimes a modest hypocellularity or mild
myeloproliferative or myelodysplastic appearance is seen, insufficient for diagnosis of a myeloproliferative
neoplasm or myelodysplastic syndrome, and genetic and flow cytometric analyses almost always are normal

Dermatologic/
integument
Ophthalmologic
Otologic/osmic
Oral/
oropharyngeal
Lymphatic
Pulmonary

Cardiovascular

Gastrointestinal

Genitourinary

Musculoskeletal/
connective tissue

Neurologic

Psychiatric
Endocrinologic/
metabolic

Hematologic/
coagulopathic
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Table 1 (continued)
System

Potential manifestations of MCAD

Immunologic

Hypersensitivity reactions, increased risk for malignancy and autoimmunity, impaired healing, increased
susceptibility to infection, increased or decreased levels of immunoglobulin of any isotype; monoclonal
gammopathy of undetermined significance (MGUS) is occasionally seen

Few patients display all of these symptoms; most display subsets, and the heterogeneity of full clinical profiles among MCAD patients
is extreme. Most symptoms are chronic and low-grade; some are persistent, but many are either episodic or waxing/waning. More
comprehensive lists and discussions, including less common symptoms, are available (e.g. [13–14]).

receptor, dominantly expressed by T-cells) and/or CD2
(ordinarily a surface adhesion molecule restricted to T/
NK-lymphocytes)], and (2) far more common patients
with “idiopathic” MCAS, which preliminary research
[15–17] strongly suggests is almost always driven by one
(largely MC-restricted, largely somatic) mutational profile
or another among a very large menagerie of such profiles
in KIT and other MC regulatory elements. Unfortunately,
such somatic mutational profiling in MCs is not presently
available in clinical laboratories, relegating such patients
to an “idiopathic” diagnosis. We acknowledge a diagnostic category of “secondary MCAS,” but its diagnosis and
treatment pales in importance compared to “primary”
and “idiopathic” MCAS given that in secondary MCAS, it is
expected that treatment of the underlying disorder, which
presumably is driving normal activation of the patient’s
exclusively normal MCs, will result in improvement of the
MCAS. As such, all mentions of “MCAS” subsequently
in this paper should be taken to refer to primary and idiopathic MCAS. Also, the behavior of cutaneous mastocytosis (CM, grossly limited to cutaneous presentation of
mastocytosis, though recent research now suggests all
cases of CM, at least in adults, can be found to have circulating, thus systemic, clonal mast cells) [18] shares far
more of the behaviors of systemic mastocytosis (SM) than
of MCAS. Therefore, all subsequent mentions of “SM”
should be taken to refer to SM and CM.

Methods
We first identified the full sets of literature revealed, as of
October 27, 2019, by searches for “mast cell activation syndrome” at both pubmed.gov (138 total articles) and scholar.
google.com (1410 total articles). We identified publications
offering new or modified schemes for diagnosing the full
range of MCAS (excluding those addressing only subsets,
such as monoclonal MCAS). We found nine such publications [7–9, 19–24], reviewed them, and found each to fall into
one of two principal schools of thought as defined by their

original papers [8, 9]. Our analysis proceeded from these
groupings, with attempts to assess each “school” for (1)
validity of diagnostic criteria, (2) diagnostic accuracy, and
(3) practicality. We also searched similarly for “hereditary
alpha-tryptasemia” (HAT) and “TPSAB1” (1 article for the
former term and 150 for the latter term at pubmed.gov, 44 for
the former and 847 for the latter at scholar.google.com) and
read the entirety of the principal papers to date [25, 26], as
well as a few selected other papers from these searches [27–
30], to garner insights into the relationships between MCAS
and the newly recognized, seemingly similar entity of HAT.

Results
Valent et al. proposal for diagnostic criteria
for MCAS
The Valent et al., or “consensus,” proposal [9] (re-termed
here as “consensus-1”) and its recent update [22] are
described in detail in the first entry in Supplementary
Table 1. (Readers are encouraged to review Supplementary
Table 1 in detail at this point in order to better understand
the following discussion regarding the various diagnostic
criteria proposals.) The “20% + 2” formula for interpreting rises in tryptase, newly introduced in this proposal,
as the sole acceptable (even “gold standard”) laboratory
parameter for diagnosing MCAS bears special attention
(again, see Supplementary Table 1).
We remain open to the possibility that “20% + 2”
(or any other formula for interpreting tryptase levels or
changes in levels) might be applicable to the broad MCAS
population, discriminating that population from the even
broader population of those without MCAS. However, we
cannot see, given the slew of issues about this formula,
that “20% + 2” can be reasonably viewed yet as a valid
(let alone sole, or “gold standard”) laboratory diagnostic
criterion for MCAS (except possibly in the two uncommon
anaphylactic settings referenced in Supplementary Table
1). It remains unclear to what extent “consensus-1” is (or
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warrants becoming) a consensus beyond that sensed by
the authors on the papers advocating these criteria.

consensus-1 criteria have published contrary assertions
(e.g. [23, 24, 36]).

Molderings et al. proposal for diagnostic
criteria for MCAS

Other proposals for diagnostic criteria for
MCAS

The original and updated Molderings et al. proposals [8,
20, 21] are described in the second entry in Supplementary Table 1. We propose that the Molderings et al. 2017
criteria [21] now be known as the “consensus-2” criteria
(to distinguish from “consensus-1”). “Consensus-2” is a
consensus, too: another set of criteria regarded by the
sizable contingent of investigators authoring this paper
as valid for diagnosing the extraordinarily complex and
variable disease that is MCAS, compared to a somewhat
different perspective held by other investigators who
first decided to label their perspective on the disease as a
“consensus.” We further note there has not yet been even
a single study comparing the validity of any one proposal
for MCAS diagnostic criteria against any other such proposal. Not that sheer popularity is a good tool for establishing scientific truth, but the consensus-2 proposal in
this paper is now endorsed by a much larger group of
investigators (from almost all medical specialties) than
in the prior Molderings et al. proposals – a group which
now collectively has seen well more than 10,000 patients
who have behaved clinically and therapeutically in a
fashion more consistent with chronic aberrant MCA than
any other known pathologic process. This consensus-2
proposal simply presents a different, somewhat “larger”
perspective, born of at least equally extensive clinical
experience as held by the consensus-1 authors, regarding the natural behavior of a large set of diseases which
appear to have a common root in chronic aberrant MC
activation, with only modestly increased MC accumulation not rising to the gross levels, and with abnormal MC
histomorphology, seen in SM.
It is not yet known which proportions of the populations afflicted by any of the many comorbidities often
seen with MCAS [e.g. myalgic encephalitis/chronic fatigue
syndrome (ME/CFS), fibromyalgia, irritable bowel syndrome (IBS), postural orthostatic tachycardia syndrome
(POTS), small fiber neuropathy (SFN), hypermobile Ehlers
Danlos Syndrome (hEDS), and many others] [12] actually
have MCAS, and whether each of those comorbidities is
truly caused by MCAS or is merely associated with MCAS.
Generally, those favoring the consensus-2 criteria have
observed non-trivial overlaps among the populations with
these diseases (e.g. [31–35]), hinting at commonalities in
these diseases’ mechanistic roots, and those favoring the

Three additional proposals [19, 23, 24] – all modest variants
of the “consensus-1” criteria – have emerged, as detailed
in the third through fifth entries in Supplementary Table 1.

Discussion
MCA disorders (largely as allergic-type diseases and more
complex presentations now termed “MCAS”) are prevalent, judging merely by the known 10–50% global prevalence of allergy (e.g. [37–43]). This figure unsurprisingly
is congruent with not only some of the higher estimates
of prevalence for MCAS [11, 44, 45] but also (given that
chronic multisystem inflammation is, more than any
other clinical feature, the sine qua non of MCAS) estimates
for prevalence of the spectrum of chronic inflammatory
diseases [43, 46, 47]. Mastocytosis, on the other hand, is
a rare disease [20]. As such, the global impact of accuracy in diagnosing MCAS likely is much greater than in
diagnosing SM.
For any disease, misdiagnosis (whether underdiagnosis or overdiagnosis) is problematic for patients and
society, typically delaying (or even permanently preventing) patients from accessing effective treatment and, thus,
perpetuating suffering and even disability and the accompanying loss of productivity. Many studies (e.g. [48–52])
have shown misdiagnosis is common, even for common
disorders. MCAD, too, is challenging to learn to recognize and challenging to diagnose [12, 34, 53]. Given the
extraordinary array of MC mediators and their extraordinary arrays of direct and indirect, local and remote, acute
and delayed and chronic effects in cells/tissues/organs/
systems throughout the body, it seems likely that MCAD
would be an area especially prone to misdiagnosis, largely
in the form of patients misdiagnosed with diseases in
truth consequential to MCAD as opposed to other diseases
(e.g. carcinoid) being misdiagnosed as MCAD. This latter
risk likely can be substantially tempered by the diagnostician’s diligence in adherence to the criteria, including
absence of processes/diseases other than chronic aberrant
MCA, which better account for the full range and duration
of the patient’s problems. Differential diagnoses for MCAS
have been considered in the literature (e.g. [20, 34]); a few
such considerations include diabetes mellitus, porphyria,
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sarcoidosis, thyroid disorders, Fabry disease, Helicobacter pylori gastritis, infectious and inflammatory bowel
and skin and genitourinary tract diseases, celiac disease,
lactose/sucrose/fructose intolerance, amyloidosis, intestinal adhesions/volvulus/obstruction, hepatitis, cholecystitis, median arcuate ligament syndrome, neuroendocrine
cancers (carcinoid, pheochromocytoma, etc.), pancreatic
endocrine tumors, food/environmental allergy, asthma,
allergic rhinitis, eosinophilic esophagitis/enteritis, other
hypereosinophilic and hyper-IgE syndromes, immunodeficiencies, autoinflammatory syndromes, hereditary
angioedema, vasculitis, hypermobility syndromes, lymphoma, myeloproliferative neoplasms, autism, anxiety/
panic, depression, psychosomatism, conversion disorder,
and Munchausen’s syndrome. As merely one example of
the intersection of MC activation with other diseases, MCs
closely interact with neurons [54, 55] and can be activated
and increased in numbers in gastrointestinal neuropathic
disease [56]. Full thickness luminal gastrointestinal tract
biopsy may be important in the diagnosis in carefully
selected cases where gastrointestinal tract dysmotility is
evident and MC disease is suspected [57], but the utility
of this approach in patients with luminal gastrointestinal
tract dysmotility overall remains unclear and needs more
research, especially given our own experience that more
commonly obtained, safer (especially given the association of MCAS with diseases of connective tissue frailty),
non-full-thickness (i.e. mucosal and submucosal) biopsies usually are sufficient for assisting in diagnosis of
MCAS (with or without gastrointestinal dysmotility) by
the consensus-2 criteria. All in all, careful consideration
by the diagnostician of the full spectrum of the patient’s
problems is needed, as well as recognition that some accurate diagnoses (e.g. chronic idiopathic urticaria), though
perhaps subsumed by a more encompassing diagnosis
of MCAS, may, nevertheless, be effectively addressed by
standard treatment for the more limited diagnosis.
The extent of unnecessary suffering from underdiagnosis of MCAS is amplified by present estimates of prognosis in MCAS of a normal lifespan in most. Delay in access
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to effective treatment for MCAS may stretch decades and
likely was present lifelong before MCAS became recognized. (Indeed, an MCAS patient’s history often will date
back to a childhood of excessive “colic,” “allergies,” “food
intolerances,” dysmenorrhea/menorrhagia soon after
menarche, and other inflammatory or allergic-type problems either incorrectly diagnosed as normal or dismissed
as of unknown cause and insignificant.) The adverse
consequences on both personal and societal scales seem
incalculable. In our collective experience, most patients
diagnosed with MCAS using the consensus-2 criteria
experience meaningful improvement – sometimes quite
astounding improvement – with MC-directed therapies no
matter the years to decades they have suffered with previously unexplained multisystem issues not infrequently
leading to partial or full disability.
Despite important agreements among the diagnostic
proposals (see Table 2), comparison reveals significant
differences. The “consensus-1” proposal – based on clinical observations of a highly experienced but relatively
small group of investigators focused principally in SM
(a disease significantly different from MCAS in key serologic, histomorphologic, and genetic factors) – considers
only severe, recurrent flares of a small number of specific symptoms as meaningful in determining a diagnosis of MCAS; the modified AAAAI proposal even requires
recurrent anaphylaxis. The “consensus-2” proposal – also
based on clinical observations of a highly experienced,
large group of clinicians and investigators increasingly
focused on MCAS – considers a far wider range of symptoms (all consistent with known effects of the established
great repertoire of MC mediators) which often respond to
MC-targeted therapies, thus making it seem reasonable
to consider, in appropriate clinical context (i.e. not with
any one symptom observed in isolation), diagnostic utility
in this larger range of symptoms. Carefully designed and
executed research will be required to identify whether
either proposal is considering the most correct range of
symptoms or should regard as diagnostically useful a
smaller – or a greater – range of symptoms.

Table 2: Broadly accepted characteristics defining the mast cell activation syndrome (MCAS) population.
1. An MCAS patient must have symptoms consistent with chronic MCA, which is aberrant (i.e. abnormal, whether constitutive/baseline and/
or reactive to some identifiable trigger; note most MCAS patients have both constitutive and reactive MCA, even if either form is just to a
modest degree at a given point), and, in many patients, accompanied by periodic flares (a.k.a. “spells,” “episodes,” and such) of certain
subsets of their symptoms
2. An MCAS patient must have signs/symptoms of aberrant MCA in multiple (i.e. at least two) organ systems
3. An MCAS patient must (with reasonable confidence) not have some other disease accounting better than MCA for the full range and
duration of the observed symptoms/signs
The characteristics listed here are a synthesis of the published proposals for diagnostic criteria for MCAS [7–9, 20–22, 24].
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The proposals differ, too, in the laboratory criteria they
consider. The consensus-1 proposal asserts (though seemingly without evidence) that a rise in serum total tryptase
by “20% + 2” ng/mL is a preferred marker of MCA, though
if a patient cannot be shown to have “20% + 2,” then elevations in a few other relatively MC-specific mediators can
be considered diagnostic. These other mediators include
prostaglandin D2 (PGD2) or its immediate 11-β-PGF2α
metabolite, and urinary histamine metabolites [generally
taken to be just N-methylhistamine (N-MH) as N-methylimidazolacetic acid (MIMA) is no longer readily testable
at clinical laboratories, at least in the United States]. The
“consensus-2” proposal states that levels of a slightly wider
range of mediators relatively specific to the MC [tryptase,
chromogranin A (CgA), heparin, PGD2, histamine, N-MH,
11-β-PGF2α, and leukotriene E4 (LTE4)], which rise above
their normal ranges can be taken as diagnostic laboratory
evidence of MCAS in the proper clinical context of otherwise unexplained chronic multisystem issues of generally
inflammatory ± allergic ± dystrophic themes. Like tryptase,
heparin is highly (though not perfectly) specific to the MC
[58], and some published research now suggests an elevated plasma heparin level likely is the single most sensitive marker of MCA, with approximately 80% of patients
clinically demonstrating symptoms consistent with MCA
showing increased levels of plasma heparin when measured using a sufficiently sensitive assay [58]. In clinical
practice, the biological and logistical challenges of measuring heparin need to be addressed to ensure accurate
results. CgA is a known product of the MC [59, 60], and if the
few other diseases known to produce elevated chromogranin A (heart or kidney or liver failure, proton pump inhibitor use, neuroendocrine cancer, chronic atrophic gastritis)
can be reasonably confidently excluded in a patient with
symptoms consistent with chronic aberrant MC mediator
release, it seems reasonable to consider that an elevated
serum CgA level likely is stemming directly from the aberrantly activated MCs. PGD2 is produced by several types of
cells [61–69], but the MC produces roughly a thousandfold
more PGD2 than any of the other types of cells [70, 71], so
when an elevated PGD2 level – in serum and/or urine – is
seen in a patient with symptoms consistent with MCA, it
seems most likely that the elevated PGD2 level is dominantly sourced from dysfunctional MCs. 11-β-PGF2α is the
principal immediate metabolic product of both PGD2 and
PGE2 [72–74]. Although the MC is known to bear receptors
for PGE2 [75–77], it appears to produce only low levels of
PGE2 [78] and does not appear to increase PGE2 production in inflammatory conditions [79], so it is possible that
elevated levels of 11-β-PGF2α may be rooted in activation of
cells other than MCs, which are producing elevated levels

of PGE2 (e.g. endothelial cells [79]). Yet, when an elevated
level of 11-β-PGF2α is seen in the context of symptoms more
consistent with MCA than other processes, it seems reasonable to consider that the elevated 11-β-PGF2α level is
sourced primarily from dysfunctional MCs. More recently,
it has been suggested that 17-β-PGD2α is the best of the PGD2
metabolites to measure in seeking evidence of MCA, but
this test is not yet routinely available at any commercial
clinical laboratories [80]. Histamine is produced by the MC
and a range of other cells [81], and it is acknowledged that
histamine, like tryptase and CgA, can be elevated in a range
of diseases and pathologic states. Yet, again, when histamine is found elevated (in whole blood, serum, plasma,
or urine) in the context of symptoms more consistent
with chronic aberrant MC mediator release than any other
known pathologic process, it seems reasonable to consider
that the elevated histamine level is sourced primarily from
dysfunctional MCs. Via histidine N-methyltransferase,
N-MH is the principal immediate metabolic breakdown
product of histamine filtered by the kidney into the urine
[82, 83], but given the range of possible cellular (and even
dietary) sources of histamine, it would seem no more feasible to pinpoint the source of an elevated N-MH on MCA
than on any other process producing an elevated level of
histamine. Thus, we again note the importance of context
in interpreting relevant findings in an MCAS patient and
assembling an overall clinical picture more supportive of
this diagnosis and less supportive of any other.
With the possible exceptions of heparin and tryptase,
it simply is not possible at present to identify the precise
range of cellular sources for each of the mediators presently proposed for testing in one MCAS diagnostic proposal
or another. Therefore, it would seem to be unnecessarily restrictive to exclude consideration of, say, histamine
testing or CgA testing simply because one can never be perfectly sure that such mediators are dominantly MC sourced.
Identification of other mast cell mediators which
might have utility in diagnosing MCAS is an area of active
investigation (e.g. [84, 85]), but questions remain regarding whether such mediators (e.g. interleukin-1β [84] and
interleukin-6, interleukin-31, tumor necrosis factor, or
vascular endothelial growth factor [85]) are “sufficiently”
specific to the MC to warrant their having significance visà-vis a diagnosis as important as MCAS. It is possible that
some MC mediators, while being of insufficient specificity for diagnostic purposes, may nevertheless eventually
demonstrate utility for therapeutic efficacy monitoring
purposes in at least some MCAS patients, i.e. in at least
some variants of MCAS.
As it is presently worded (in both the original proposal in 2012 and the “update” in 2019), the “consensus-1”
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proposal requires that MCAS patients demonstrate at least
partial response to antihistamines and/or cromolyn as an
essential diagnostic criterion, while the “consensus-2”
proposal permits demonstration of such a response to be
considered a minor diagnostic criterion. It is understood
that both diagnosis and therapy are imprecise arts, and
it often is the case in practice that therapeutic response
(or lack thereof) leads to alterations in diagnostic thinking. However, we are unaware of other diseases for which
diagnostic criteria require demonstration of therapeutic
response. Generally, it is acknowledged that diagnosis
is what should principally inform therapeutic decision
making. It is concerning, too, that treatment response be
required to establish diagnosis of a disease of complexity so great it seems virtually certain that at least some
patients might not respond to any of the therapies presently known to have utility in some patients. Accurate
diagnosis would still be important in such patients visà-vis forthcoming treatments. It also is concerning that
specification of such a limited set of treatment options in
a proposal for diagnostic criteria might suggest to most
practitioners that if the patient does not respond to any
of these few treatments, then it must not be possible for
the patient to have the disease – a precept which is highly
unlikely given, again, the extraordinary complexity and
heterogeneity of the disease (implying, and as has actually been found, a large array of treatments found helpful
in various patients). Thus, in an effort to avoid underdiagnosis – especially of a disease which, once diagnosed,
usually is effectively treatable in one fashion or another
– listing of specific treatments in a set of diagnostic criteria would seem to be counterproductive. In our experience, the range of treatments effective in patients meeting
“consensus-2” criteria is far broader than those listed in
the “consensus-1” criteria.
Although none of the published proposals for diagnostic criteria for MCAS comprehensively specifies the
types or numbers of mast cell stabilizers or mediator
antagonists, doses, or durations which should be tried to
establish the therapeutic response considered by some
proposals as a required or optional diagnostic criterion,
treatments commonly tried early, at standard doses as used
in most other applications, include H1 and H2 histamine
receptor antagonists, leukotriene receptor antagonists,
cromolyn, and, in patients without prior adverse reactions
to such, non-steroidal anti-inflammatory drugs. Treatment response criteria (e.g. “partial response,” “complete
response”) have not yet been defined by any group, and
this is likely to be a challenging endeavor in itself given
that the complex (patho)physiology of the disease sometimes results in finding unexpected benefits rather than
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expected benefits. Clinical judgment, taking into account
observed symptoms and findings and known mast cell
(patho)physiology, is appropriate in treating MCAS, often
starting inexpensively. Setting aside the observation that
rapid demonstration of intolerance of a drug being tried
for MCAS should immediately invite cessation of the drug
and consideration of potential excipient-driven reactivities, in our estimation most drugs tried for MCAS which do
not demonstrate clear benefit by 2–4 weeks after having
reached a “reasonably potent” dose should be abandoned
out of futility. A comprehensive review of the pharmacotherapy of MCAS has been published [86].
The theme we are constantly reminded in our considerations of various proposals for diagnostic criteria
for MCAS is that MCAS is a very complex disease from the
clinical to the molecular level (including mediators, genes,
and epigenes) [11, 15–17, 80]. As such, a clinical diagnosis
of MCAS – i.e. a case of MCAS worthy of treatment – virtually certainly will never rest on meeting merely a single
diagnostic criterion (e.g. a single laboratory test meeting
a specific threshold). As is the case with most syndromes,
the diagnosis of MCAS will continue for many years to
come to rest on the demonstration of a specific constellation of findings, i.e. the presence of each finding in the
context of other findings also congruent with the diagnosis.
In such a scheme, where the presence of multiple criteria creates a natural system of “checks and balances,” the
likelihood of misdiagnosis based on inappropriate interpretation of any one observation in the patient dramatically diminishes.

How does familial hypertryptasemia fit into
the mast cell disease construct?
First described merely a few years ago by investigators
in Spain [25] and at the U.S. National Institutes of Health
[26], familial hypertryptasemia, also termed hereditary
alpha-tryptasemia (HAT), has been defined as a chronically elevated serum tryptase level coincident with the
finding of redundant copies of the alpha tryptase gene
TPSAB1 (though even that definition has been challenged
by the finding that ~8% of the patients with redundant
TPSAB1 have no elevations in tryptase). HAT appears to be
prevalent (approximately 4–6% of the population), and
the described clinical spectrum of HAT seems to fit well
within that of MCAS. Thus far, no differences have been
identified between prognosis or recommended management for HAT patients vs. MCAS patients, and the finding
of HAT patients with normal tryptase levels raises other
questions. To what extent (if any) are the elevations in
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tryptase seen in most HAT patients, and the redundant
TPSAB1 genes seen in all HAT patients (by definition),
actually causing the chronic aberrant MC release of a wide
range of mediators suggested by the wide range of symptoms in these patients (as in most MCAS patients)? Or, is
TPSAB1 redundancy merely associated with other mutations more responsible for driving the aberrant constitutive and reactive MC mediator release in HAT patients?
Furthermore, although the principal function of tryptase
is not yet known [87, 88], the range of what is known about
tryptase’s biological functions makes it unlikely that the
modest elevation in tryptase seen in most HAT patients
would be the driver of any of their symptoms, let alone
most or all of their symptoms. As such, it seems likely that
the redundant TPSAB1 genes and the modestly elevated
tryptase levels in HAT patients are associated with, but
not causative of, the MCAS-like symptoms catalogued in
most HAT patients. At present, then, HAT appears to us
to be merely one of the myriad of subsets of MCAS (such
as some of the rare inborn autoinflammatory syndromes
are increasingly appearing to also be). Therefore, given
that there are no prognostic or therapeutic differences
yet identified between HAT and MCAS, it would appear
that the only utility in TPSAB1 testing is in investigative
settings and in pursuing a diagnosis of MCAS per consensus-2 criteria in patients with a persistent, mild tryptase
elevation (e.g. ≤20 ng/mL), as such a finding (inferring
the elevated tryptase level might be stemming from the
TPSAB1 redundancy and that such a redundancy might
actually be merely an incidental finding with no clinical
effects) might then incline the diagnostician to search for
additional (non-tryptase-based) laboratory evidence of
MCA before making a definitive diagnosis.

Why the rush?
This question is imperative in judging at this time the
validity/utility of the various proposals for MCAS diagnostic criteria. At this very early point in our understanding
of an obviously extremely complex disease (as one would
expect of a disease rooted in a cell intrinsic to the survival of all eukaryotes for >500 million years now) [89],
it is unclear why only one proposal for diagnostic criteria should be considered acceptable. There likely will be
many revelations to come in the basic and clinical sciences of MCA, which will significantly affect valid MCAS
diagnostic criteria. Despite the problems readily apparent
with the consensus-1 proposal for diagnosing MCAS, it
need not be dismissed or replaced at this time. Instead,
there presently seems to be ample room for using both the

consensus-1 and consensus-2 proposals (and likely others,
too) for diagnosing MCAS (analogous to how evolving, steadily more complicated proposals for diagnostic
schema for mastocytosis, sometimes with “provisional”
declarations, frequently emerge), especially as it seems
increasingly likely that the consensus-1 criteria simply
diagnose a severe but fortunately small subset of the
patients diagnosed by the consensus-2 criteria. We thus
propose that either the consensus-1 or consensus-2 proposal be accepted for diagnosing any given case of MCAS
until criteria can be developed using the modern, robust
methodologies now being employed to create classification criteria for similarly complex and heterogeneous
conditions such as lupus [90]. It has been little more than
a decade since the first case reports of MCAS were published; there have not yet been any large-scale studies of
any aspects of the disease, though a few small-scale such
studies are beginning to emerge [12, 33, 91]. As such, we
fail to see why there must be a rush to pronounce only one
approach as definitively diagnostic of a disease of such
complexity/heterogeneity. We acknowledge there would
be advantages to a single approach (principally, comparability of patient populations for research purposes,
thought it should be noted that mutational studies to date
(e.g. [15–17]) have shown great mutational heterogeneity in all MCAS patient populations so studied thus far,
thus questioning the very feasibility of studying homogeneous MCAS populations). On the other hand, it seems
likely there would be significant drawbacks (principally,
underdiagnosis from inappropriately narrow criteria) to
making premature judgments about diagnostic criteria
for such a yet poorly understood complex/heterogeneous
entity. If alternative ways come to be recognized to diagnose a disease whose clinical behavior seems more easily
attributable to chronic MCA than any other recognizable
process – and especially when such diagnoses clearly lead
to effective treatments benefiting previously unimprovable patients – then why not at least tentatively accept
multiple diagnostic approaches with open arms and allow
the time needed to adequately vet the true validity of any
given diagnostic proposal? The perpetuated suffering, and
occasionally even mortality, consequent to underdiagnosis seems counter to the fundamental goal and guiding
principle of all forms of medicine.

Drawbacks in practice and in research to two
different diagnostic proposals
As implied above, the principal drawback in clinical
practice, and, even more importantly, in research, to the
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persistence of two proposals for diagnostic criteria for
MCAS is obvious: the inability to compare populations
diagnosed by one set of criteria against populations diagnosed by the other set of criteria.
It is obvious that incomparability is a substantial
drawback. In clinical practice, diagnostic assessment
tools which fit well with one proposal may not fit well with
other proposals; treatment approaches (individual drugs,
algorithms, etc.) which work well for MCAS diagnosed by
one proposal may not work as well for MCAS diagnosed
by any of the other proposals. In research, incomparability obviously limits a study’s applicability to the population in general and thus diminishes the overall value of a
study, certainly not an insignificant consideration in these
days of substantial clinical trial costs.
Another drawback is clear, too: practitioners may find
an already complex field rapidly becomes unmanageably
complex in trying to understand which diagnostic and
therapeutic approaches will best apply to the individual
patient. Some practitioners may use unmanageable complexity as a reason not to consider the diagnosis at all.
Of course, to expect simplicity in diagnostic criteria in
such a complex disease would seem to be folly, and though
it is less pleasant to deal with complexity than to deal with
simplicity, MCAS is the complex beast that it is. Though
it is always desirable to try to reduce complexity, at some
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point complexity cannot be reduced further without incurring unacceptable adverse consequences.
Fortunately, these drawbacks, in fact, do not preclude
pursuing clinical research in MCAS; they merely complicate the matter, an outcome which seems unavoidable and
perhaps should be embraced (as an opportunity to better
understand the many variants of the disease) rather than
feared or avoided. Friendly competition among proposals
for diagnostic criteria even sets a stage upon which clinical trials can rigorously compare proposal performance
– certainly a worthy objective expected to help the field
progress toward harmonization of proposals, and, in the
end, improved clarity for patients and practitioners alike.

Suggested steps forward in practice
MCAS likely is prevalent [11]. As such, ignorance or diminishment of it disserves individual patients as well as
society at large, raising costs to the health care system
and diminishing worker productivity. The disease is
complicated and will become ever more so as its pathophysiology is increasingly unraveled and as its likely great
many distinct variants come to be identified. Therefore,
it seems the greatest human good would come first from
diagnosis – by any set of peer-reviewed, published criteria

Table 3: Suggested steps forward in MCAS practice in 2020.
1. We advocate diagnosing MCAS in routine clinical practice based on either of the two peer-reviewed, published proposals for diagnostic
criteria for MCAS [i.e. the latest iteration of consensus-1 [22] (or its more neuro-inclusive predecessor [9]) or the latest iteration of
consensus-2 [21]], thereby giving the patient access to concerted therapeutic efforts which are likely to gain significant improvement
the patient (and society) will enjoy for decades to come. In other words, although the preference for science-grounded practice by all
health care professionals is recognized, nevertheless, when prioritization becomes necessary, our authorship – a broad collaboration of
academicians and community practitioners, generalists and specialists of all sorts, including physicians and a broad array of other health
care professionals, representing truly global thought in this area across five countries on three continents in both hemispheres – strongly
recommends that practitioners serve human needs first and science second.
2. Therapies supported by peer-reviewed published evidence obviously are to be preferred over those without such, and higher grades of
evidence obviously are to be preferred over lower grades. Also, it almost always is better to pursue truly novel therapies in the context
of an appropriately designed, approved, and monitored clinical trial. However, again, it is merely a decade since the first case reports
of MCAS were published, and thus a paucity of published evidence supporting various therapies, and many defects in trial design and
execution, must be expected for decades to come. These deficiencies should not hinder efforts at applying treatments with reasonable
risk:benefit ratios as (1) most of the present treatments for MCAS bear little risk at the doses typically effective in MCAS, and (2) again,
most MCAS patients do manage to eventually identify significantly helpful treatment even in spite of having suffered progressive sickness
and debility from their illness for decades. There are many reasons to expect it will take a long time before our profession learns how
to design and conduct MCAS studies well and to make truly reliable conclusions from such research. We may know very little thus far
about MCAS, but even just the little we do know is turning out to be enough to significantly help most MCAS patients. Thus, it would be a
shame for our profession if many such patients were to continue suffering for decades, years, or even a month longer than necessary just
because a perfect, unified set of diagnostic criteria or clearly reliable therapeutic guidance is not yet available.
3. As awareness of MCAS within the general medical community widens, the pace of research, including the opening of clinical trials, will
accelerate. As can be said for any disease, advancement of the science usually comes best from rigorous research, so clinicians are
strongly encouraged to remain abreast of research developments and opportunities (e.g. periodically searching clinicaltrials.gov for
“mast cell” or “mast cell activation syndrome,” or subscribing to research notification services) and to enroll their MCAS patients in
clinical trials (whether diagnostic, therapeutic, or even merely studying the natural history) to the extent feasible.
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– and then from attempted treatment with any therapy
which has been found helpful in at least some population
of MCAS patients. Such generalities, of course, neither
excuse MCAS-treating clinicians from being judicious in
use of diagnostic criteria and in selection of therapies to
be tried (especially given the extreme costs of some therapies) nor excuse MCAS investigators from pursuing welldesigned and -executed studies to make clear the manners
in which assorted specific variants of the disease behave,
both in their natural courses and in response to various
treatments. Further practice recommendations are noted
in Table 3.

Suggested steps forward in research
As previously noted, the complexity of MC biology (especially the large number of mediators produced by the MC
and each mediator’s typically large menagerie of effects),
together with the data to date suggesting a menagerie of
mutations (mostly somatic) is present in the dysfunctional
MCs in most primary MCAS patients [15–17], inescapably
creates a very large pool/collection of variants of MCAS.
Each variant has its own complex pathophysiology, with
similarities among some cases of MCAS but also many
differences which seem likely to be among the principal

Table 4: Suggested steps forward in MCAS research in 2020.
1. Given the challenges created by the complexity and heterogeneity of MCAS, and though recent trends in the conduct of clinical trials have
emphasized diversity in the recruiting of subjects, MCAS would seem to be an investigational arena calling for even greater precision in
eligibility criteria, and restriction in diversity, than have historically been defined. In fact, given the likely significant prevalence of MCAS
in the general population, together with the extreme heterogeneity of the disease’s behavior at all levels, even the eligibility criteria
for “healthy control subjects” probably could stand some “tightening” to ensure (to a reasonable, affordable extent) that such subjects
likely do not harbor MCAS. For example, in a study investigating mast cell densities in luminal gastrointestinal tract biopsies, it would
be insufficient to use “routine screening colonoscopy” patients as “healthy control subjects” unless careful histories have been taken
from, and physical examinations conducted on, such subjects by an MCAS-familiar clinician to provide reasonable assurance they likely
do not have MCAS. Otherwise, the “healthy control” cohort could become sufficiently “contaminated” by subjects with unrecognized
MCAS as to impair the study’s ability to detect distinctions between healthy people and MCAS patients. Examples abound with significant
adverse consequences in practice arising from poor clinical trial design leading to false conclusions of differences between “control” and
“affected” cohorts. The complexity of MCAS would seem to only heighten the risk for such consequences unless similarly heightened care
is taken with regard to trial design.
2. Unless it is specifically the heterogeneity of MCAS one is seeking to characterize in a study (e.g. [12]), studies examining “general”
populations of MCAS patients probably are inadvisable, at least until diagnostic evaluation for MCAS advances to where identification
of the MC mutational profiles likely driving most cases of the disease are routine and provide some expectation of harmony in clinical
behavior among the patients recruited for a given study.
3. It seems more appropriate to design MCAS-related studies focused specifically in cohorts with certain associated co-morbidities
suspected to be underpinned by one particular variant (or a relatively small collection of variants) of MCAS. Perhaps a good starting
point would be to develop a small “industry” of pilot studies examining the prevalence of laboratory-proven MCAS (as diagnosed by one
diagnostic criteria proposal or another, per the preference of an individual study’s investigators) within cohorts of patients with one
co-morbidity or another [e.g. myalgic encephalitis/chronic fatigue syndrome (ME/CFS), fibromyalgia, irritable bowel syndrome (IBS),
postural orthostatic tachycardia syndrome (POTS, hyperadrenergic (haPOTS) and otherwise), hypermobile Ehlers-Danlos syndrome
(hEDS), etc.]. At a minimum, this approach would permit the prevalence of laboratory-proven MCAS (whether primary, secondary, or
idiopathic) within the cohort with that co-morbidity to be defined, perhaps showing, for at least some of those co-morbidities, a nontrivial prevalence of MCAS and thus a possible new etiologic consideration for at least certain fractions of the populations with these
various co-morbidities which have long defied great extents of etiologic investigations.
4. Whenever possible, such initial comorbidity-specific MCAS-prevalence studies should be accompanied simultaneously by correlative
science studies in which, similar to prior studies [15–17], MC mutational profiles (and epigenetic profiling, too, if feasible) are sought in
the studied subjects. Given that the subjects studied in the prior studies were “general MCAS patients,” with great heterogeneity in their
clinical presentations, it is not surprising that such great heterogeneity was also found in the studied subjects’ MC mutational profiles.
However, it is possible, perhaps even likely, that studies of the MC mutational profiles in cohorts of MCAS patients sharing similar
clinical presentations (e.g. a cohort of patients with only hEDS, or at least with hEDS and a very limited range of additional comorbidities)
might discover recurrent mutational profiles (in genomes and even epigenomes) which might be essential in finally unraveling the full
pathobiology of hEDS and the many other comorbidities found among the “general MCAS population.”
5. The design of studies investigating molecular mechanisms for the various clinical (mis)behaviors seen in some MCAS patients should
take into consideration that not all of the dysfunctional MCs in an MCAS patient are dysfunctional in the same manner or at the same
time. As such, study design probing local, brief expression of (often quite thermolabile) MC mediators may be more revealing than study
design probing systemic, sustained mediator expression. Such studies may well first require development of new technologies, including
molecular radiographic technologies such as whole-body imaging of expression of a potent vasodilator such as PGD2 during a flare of
presyncopal symptoms in a patient with laboratory-proven haPOTS and MCAS.
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challenges of MCAS to the diagnostician. It can be challenging to recognize that MCAS should be considered in
differential diagnosis of a patient’s presenting assortment
of symptoms and findings when the clinical presentation
can substantially differ from one patient to the next. The
disease even can vary substantially in its behavior within
a given patient from one point in time to another (e.g.
alternating diarrhea and constipation are common), and
even from one site to another in the same patient at the
same point in time (e.g. osteopenia/osteoporosis at some
bony sites and, simultaneously, osteosclerosis at other
sites). These multiple dimensions of heterogeneity create
tremendous problems for rigorous study of the disease.
Each patient in a study of “general” MCAS patients may
well be more of an “N of 1” than seen with each patient
in studies of most other diseases, making it very difficult
to reach definitive conclusions and quite possibly missing
important diagnostic and therapeutic signals present only
in various subsets of the MCAS population. We summarize
our recommendations for addressing these challenges in
Table 4. Clearly, the complexity and heterogeneity of MCAS
and the challenges to research posed by various essential
elements of MCAS biology/pathobiology such as the brief
half-lives and thermolability of many of the MC’s mediators constitute further reason to expect the road ahead in
this arena will be difficult and slow and further reason
for measured consideration of diagnostic and therapeutic
recommendations rather than rushes to judgment.

Conclusions
Mast cell activation syndrome (MCAS) is a recently recognized clinical entity increasingly appreciated to be
the correct root diagnosis (i.e. implying response to corresponding therapy) for a large number of patients previously found to have a large assortment of seemingly
idiopathic chronic multisystem issues of general themes
of inflammation ± allergic-type issues ± dystrophisms.
MCAS is extraordinarily complex and heterogeneous in
its clinical behavior, and as so much remains to be discovered about the underlying biology and pathobiology of
the MC, it seems likely that appreciation of the full range
of clinical (let alone molecular) behavior of the disease
will continue expanding for decades to come. Given such
expectations, it seems wise to remain receptive to at least
some variation in views of the disease’s behavior and of
appropriate diagnostic and therapeutic management, and
to welcome new views which, taking advantage of new
research, may explain more observations than perhaps
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afforded by older views. Risk of overdiagnosis likely can
be managed relatively well by adhering to peer-reviewed,
published criteria. All in all, there is space for many years
to come to accommodate not only both the consensus-1
and consensus-2 proposals for diagnosing MCAS but also
other proposals which may emerge. It seems likely that
far more research will be needed before it may become
appropriate to make a concerted effort to harmonize discordant proposals. We recognize the WHO for its insight in
this matter as manifested by its not considering MCAS in
its recent revision [92] of its consensus diagnostic criteria
for mastocytosis, and we caution against premature conclusions at other upcoming meetings given the marked
individual and societal risks from underdiagnosis of what
likely is a very prevalent disease.
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